Vicplas International (SGX:569), a medical devices and pipes manufacturer, expects to record a consolidated loss after tax of less than SG$1.8 million for the financial year ended July 31, 2024, reversing a S$4.2 million profit the previous year, according to a Tuesday filing on the Singapore Exchange.
The loss is being attributed to challenges in its medical devices segment, including lower sales as customers adjusted post-pandemic inventory levels, and higher costs linked to its Changzhou plant expansion and the startup of a new facility in Juarez, Mexico.
Despite this, the group's adjusted EBITDA is expected to remain positive, between SG$6.5 million and SG$7.5 million, compared to SG$14.7 million last year, supported by its pipes and pipe fittings segment.
Price (SGD): S$0.10, Change: S$+0.0010, Percent Change: +1.04%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。